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        Mammalian hematopoiesis involves the genera-
tion of blood cells from a common hematopoi-
etic stem cell (HSC) through many intermediate 
stages, each of which can give rise to various 
types of malignancies upon their dysregulation. 
However, the molecular mechanisms that gov-
ern this process are incompletely understood. 
In particular, the quantitative decisions regarding 
how many cells take which pathway of matura-
tion remain obscure. Most studies of this pro-
cess have focused on cytokines and transcription 
factors, which can control cellular proliferation 
and diff  erentiation decisions (  1  ). MicroRNAs 
(miRNAs) are a novel class of small, regulatory 
RNA molecules that play evolutionarily con-
served roles in cellular development and func-
tion, and mediate target gene repression through 
3     untranslated region (UTR) interactions (  2  –  4  ). 
Recently, a growing body of evidence has im-
plicated specifi  c miRNAs in the modulation of 
mammalian hematopoiesis during both physio-
logical and pathological conditions (  5, 6  ). 
  Among miRNAs expressed by hematopoi-
etic cells,   miR-155   has emerged as having signifi  -
cant impact on the biology of lymphocytes (  7  –  9  ). 
  MiR-155   is up-regulated to high levels in re-
sponse to B or T cell receptor engagement 
(  10, 11  ) and plays a B cell  –  intrinsic role in ger-
minal center formation and subsequent antibody 
production in vivo after antigen challenge (  8, 9  ). 
Furthermore,   miR-155    –  defi  cient T cells exhibit 
a Th2 bias, likely through repression of c-Maf. 
Beyond its apparent contribution to the humoral 
immune response, the need to properly regulate 
  miR-155   levels is suggested by its dramatically el-
evated expression in several types of human B cell 
lymphomas (  11  –  13  ), and its reported suffi   ciency 
in triggering B cell lymphoma when overex-
pressed in a B cell  –  restricted manner in mice (  7  ). 
  In contrast to the emerging picture of   miR-
155   functions in lymphocytes, the role or conse-
quences of   miR-155   expression in hematopoietic 
cells of myeloid origin have been largely un-
characterized. Our group recently reported high 
levels of   miR-155   expression in cells of the in-
nate immune system, such as monocytes and 
macrophages, after exposure to infl  ammatory 
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B cell (B220  +  ), and erythroid precursor (Ter-119  +  ) popula-
tions by 24 h after LPS treatment (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20072108/DC1), sub-
stantial expansion of GM cells and reductions in B cells 
and erythroid precursors were evident by 72 h (  Fig. 1 C  ), 
consistent with a previous study (  17  ). Histological analyses also 
showed myeloid preponderance and hyperplasia, with relative 
stimuli (  14, 15  ). As in lymphocytes,   miR-155   expression is 
tightly regulated in myeloid cells, suggesting a specialized 
function during times of infl  ammatory stress. Interestingly, 
the infl  ammatory process is known to have a signifi  cant impact 
on hematopoiesis by enhancing production of granulocyte/
monocyte (GM) populations to replenish those that become 
depleted while combating infection (  16, 17  ). This develop-
mental reprogramming is driven in part by cytokines and 
growth factors produced during infl  ammation, and by direct 
recognition of pathogen-associated molecular patterns, such as 
LPS by mammalian Toll-like receptors expressed on hemato-
poietic stem and progenitor cell populations (  18  ). Because 
  miR-155   is part of the Toll-like receptor  –  induced gene pro-
gram, we have examined its potential role in regulating GM 
expansion in the bone marrow during infl  ammation. 
  In this study, we demonstrate that   miR-155   expression is 
greatly increased in mouse bone marrow cells after LPS injection 
and is suffi   cient to drive GM expansion when constitutively 
expressed in mouse HSCs in vivo. However, sustained expres-
sion of   miR-155   also leads to several features characteristic of 
pathological myeloid proliferations, correlating with its over-
expression in samples from human acute myeloid leukemia 
(AML) patients. Finally,   miR-155   directly repressed a broad 
range of target mRNAs implicated in myeloid hyperplasia and/
or hematopoiesis. These data suggest an important physiological 
role for   miR-155   in GM expansion during times of infl  am-
mation, yet underscore the importance of its proper regula-
tion for maintaining the balance between an effi   cient immune 
response and the potential for inducing malignant disease. 
    RESULTS   
  LPS induces bone marrow expression of   miR-155   
before myeloid expansion in vivo 
  Although   miR-155   is expressed at low levels in mice under 
steady-state conditions, we examined whether its expression 
is elevated in the bone marrow compartment after the on-
set of infl  ammation in vivo, as seen in cultured macrophages 
(  14  ). Mice were injected i.p. with a sublethal dose of LPS 
(50     g) or PBS control, and their bone marrow cells were 
analyzed for   miR-155   expression. Strong induction of   miR-
155   levels were observed after 24 h of LPS treatment, which 
returned to control levels by 72 h (  Fig. 1 A  ).   Up-regulated 
  miR-155   expression was also detected upon direct LPS or 
GM-CSF stimulation of isolated bone marrow cells from 
WT or Rag1      /      mice, demonstrating that cells other than 
mature B and T lymphocytes contribute to this response 
(  Fig. 1 B  ). Furthermore, both populations enriched in ma-
ture cells (Mac-1, B220, and Ter-119 positive), and those 
enriched in immature cells (Mac-1, B220, and Ter-119 low 
to negative) responded to LPS by up-regulating   miR-155  , with 
the immature population having a distinctly stronger response 
than the mature (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20072108/DC1). 
  In addition to   miR-155   expression, we also monitored bone 
marrow cell dynamics in response to LPS in vivo. Although 
there was little change in bone marrow GM (Mac1  +   Gr1  +  ), 
    Figure 1.         LPS treatment induces bone marrow expression of   miR-155   
before GM expansion.   (A) WT mice (  n   = 3 per group) were injected i.p. 
with 50     g LPS dissolved in PBS or PBS alone. RNA was collected from 
total bone marrow cells, and   miR-155   expression was assayed by quanti-
tative PCR (mean   ±   SD). (B) Bone marrow was fl  ushed out of the femurs 
and tibias of WT and Rag1     /     mice  ( n  = 3 per group), stimulated with 
100 ng/ml LPS, 100 ng/ml GM-CSF (GM), or medium (M) for 24 h, and RNA 
was then assayed for   miR-155   expression levels (mean   ±   SD). NC, no tem-
plate control. (C) BM cells collected from mice in A at the 72-h time point 
were stained with antibodies against Mac1, Gr1, B220, Ter-119, or CD4 
and analyzed by FACS. (D) Wright-stained bone marrow smears (bottom; 
bar, 25     M) or hematoxylin and eosin  –  stained bone marrow sections (top; 
bar, 60     M) from WT mice injected with LPS or PBS for 72 h.     JEM VOL. 205, March 17, 2008 
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erythroid hypoplasia, after 72 h of LPS treatment (  Fig. 1 D  ). 
Collectively, these data indicate that LPS-induced   miR-155   
expression in the bone marrow precedes GM cell expansion. 
  Enforced expression of   miR-155   in HSCs causes 
a myeloproliferative disorder in the bone marrow 
  We next investigated whether   miR-155   is suffi   cient to medi-
ate GM expansion in the mouse bone marrow in vivo. Ret-
roviral-mediated gene transfer was used to force expression of 
GFP and   miR-155   in HSCs (  Fig. 2 A  ), followed by engraft-
ment of these cells into lethally irradiated C57BL6 mouse 
recipients.   By 2 mo after reconstitution, mice were killed and 
coexpression of   miR-155   and GFP was detected in various 
hematopoietic tissues, including the bone marrow (  Fig. 2 B  ), 
thymus, spleen, and lymph nodes (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20072108/DC1). Control 
mice only expressed GFP but not   miR-155  . 
  Gross analyses of femurs and tibias from mice expressing 
  miR-155   revealed a white-tan bone marrow coloration unlike 
the vibrant red seen in controls (  Fig. 2 C  ). Upon microscopic 
inspection of hematoxylin and eosin  –  stained bone marrow 
sections and Wright-stained bone marrow smears (  Fig. 2 D  ), 
  miR-155    –  expressing bone marrow was dominated by GM 
cells at a variety of either normal or abnormal developmental 
stages based upon their morphology. Indeed, many of the cells 
that appeared to be granulocytic precursors showed irregular 
segmentation of their nuclei and lacked condensation of nu-
clear chromatin (  Fig. 2 E  ). Conversely,   miR-155   expression 
also led to a reduction in erythrocytes, megakaryocytes, and 
lymphocytes in the bone marrow (  Fig. 2 D  ). 
  Flow cytometry identifi  ed approximately twice as many 
Mac1  +   GR1  +   GM cells, very few Ter-119  +   erythroid pre-
cursors, and a reduction in B220  +   B cells in the bone marrow 
of mice expressing   miR-155   versus the control vector (  Fig. 2 F  ). 
When gated on GFP  +   cells (expressing   miR-155  ), there was a 
dramatic increase in large granular cells, as defi  ned by having 
high forward scatter (FSC) and side scatter (SSC), respec-
tively (  Fig. 2 G  ). Back-gating confi  rmed that these cells were 
Mac1  +  , with a majority also positive for Gr1. Furthermore, 
the cells responsible for the overall GM, B, and erythroid 
precursor diff  erences were largely GFP  +   (  Fig. 2 H  ). These ob-
servations reveal profound myeloid proliferation with dys-
plastic changes in the bone marrow of mice expressing  miR-155   
compared with controls. 
    MiR-155   expression in HSCs causes splenomegaly 
and extramedullary hematopoiesis 
  Splenomegaly was observed in   miR-155    –  expressing com-
pared with control mice (  Fig. 3 A  ).   Hematoxylin and eosin 
staining of splenic sections from   miR-155    –  expressing mice 
revealed expanded interfollicular regions containing various 
hematopoietic elements, as well as constricted and disrupted 
B cell follicles compared with control spleens (  Fig. 3 B  ). 
Upon analyses of Wright-stained splenic touch preparations, 
we observed a large number of erythroid precursors, mega-
karyocytes, and some developing GM cells in the spleens of 
    Figure 2.         Expression of   miR-155   in HSCs causes a myeloprolifera-
tive disorder in the bone marrow.   (A) Depiction of the retroviral con-
struct used to enable both   miR-155   and GFP expression in HSCs. (B) Bone 
marrow cells of mice reconstituted with MG155- or control vector  –  trans-
duced HSCs were analyzed for their expression of GFP by FACS, where the 
percentage of GFP  +   cells is indicated. Black line, C57BL6 control; gray line, 
MG155 or control vector. Cells from the same compartments were 
  analyzed for   miR-155   expression using quantitative PCR (mean   ±   SD). 
(C) Tibias were removed from mice reconstituted with MG155 or control 
vector HSCs for 2 mo, or untreated C57BL6 (B6) mice, and photographs 
were taken. (D) Hematoxylin and eosin  –  stained bone marrow sections 
from   miR-155    –  expressing or control mice (top; bar, 60    M).  Wright-
stained bone marrow smears from mice reconstituted with MG155 or 
control vector HSCs (bottom; bar, 25     m). (E) Examples of dysplastic my-
eloid cells observed in   miR-155    –  expressing bone marrow are enlarged. 
(F) Number of specifi  ed cell types found in the bone marrow (one femur 
plus one tibia) of mice reconstituted with MG155 or control vector HSCs 
(mean   ±   SD). (G) GFP-gated bone marrow cells from mice reconstituted 
with MG155 or control vector HSCs were analyzed for FSC and SSC 
counts and expression of Mac1 and Gr1. (H) Bone marrow cells from mice 
reconstituted with MG155 or control vector HSCs were analyzed for ex-
pression of Mac1, Ter-119, or B220 on both GFP  +   and  GFP       cells by FACS. 
Data represent at least six independent animals in each group, and 
p-values (*) of   <  0.05 were considered signifi  cant after a Student  ’  s 
two-tailed   t   test.   588    MIR-155   CAUSES A MYELOPROLIFERATIVE DISORDER | O  ’  Connell et al.
155    –  expressing spleens was largely negative for GFP, possibly 
arising from nontransduced HSCs. These results clearly dem-
onstrate the presence of splenic extramedullary hematopoiesis 
in   miR-155    –  expressing mice, likely compensating for the bone 
marrow defects. 
  Expression of   miR-155   in HSCs perturbs peripheral blood 
cell populations 
  Consistent with the disrupted hematopoiesis observed in   miR-
155    –  expressing mice, their peripheral blood demonstrated 
several distinct abnormalities compared with controls. By 2 mo 
after reconstitution, FACS detected signifi  cantly elevated 
numbers of Mac1  +   cells (  Fig. 4 A  ), and Wright-stained blood 
smears revealed the presence of morphologically abnormal 
GM cells in   miR-155    –  expressing mice (  Fig. 4 B  ).   Complete 
blood cell counts showed a signifi  cant reduction in red blood 
cell, hemoglobin, and platelet levels (  Fig. 4 C  ), FACS found 
  miR-155    –  expressing mice, whereas very few of these cell types 
were observed in control spleens (  Fig. 3 B  ). 
  FACS analyses corroborated these observations. We saw 
  elevated numbers of Mac1  +   Gr1  +   myeloid cells and Ter-119  +   
erythroid cells, with little change in CD4  +   T cells and B220  +   B 
cells in   miR-155    –  expressing compared with control spleens 
(  Fig. 3 C  ). When gated on GFP  +   cells (expressing   miR-155  ), 
there were elevated numbers of large granular cells, as defi  ned by 
having high FSC and SSC, respectively, with a majority co-
expressing Mac1 and Gr1 (  Fig. 3 D  ). Furthermore,   miR-155    –
  expressing splenocytes contained overall higher numbers of 
Mac1  +   cells that expressed GFP compared with controls 
(  Fig. 3 E  ). Conversely, the Ter-119  +   cell population from   miR-
    Figure 3.         Expression of   miR-155   in HSCs triggers extramedullary 
hematopoiesis in the spleen.   (A) Spleens were removed from mice re-
constituted with MG155 or control vector HSCs for 2 mo, and photographs 
were taken (top). Spleen weight was also determined in the two groups 
(bottom; mean   ±   SD). (B) Hematoxylin and eosin  –  stained sections (top; bar, 
200     m) or Wright-stained touch preps (bottom; bar, 25     m) from mice 
reconstituted with MG155 or control vector HSCs. (C) Number of specifi  ed 
cell types found in the spleens of mice reconstituted with MG155 or con-
trol vector HSCs (mean   ±   SD). (D) GFP-gated spleen cells from mice recon-
stituted with MG155 or control vector HSCs were analyzed for FSC and 
SSC counts and expression of Mac1 and Gr1. (E) Splenocytes from mice 
reconstituted with MG155 or control vector HSCs were analyzed for 
expression of Mac1, Ter-119, CD4, or B220 on GFP  +   and  GFP       cells  by 
FACS. Data represent at least six independent animals in each group, and 
p-values (*) of   <  0.05 were considered signifi  cant using a Student  ’  s 
two-tailed   t   test.   
    Figure 4.         Expression of   miR-155   in HSCs perturbs peripheral 
blood cell populations.   (A) Peripheral blood was collected from mice 
reconstituted with MG155 or control vector HSCs for 2 mo and analyzed 
by FACS to determine FSC and SSC counts and expression of Mac1. The 
total number of Mac1 cells was also determined. (B) Photomicrographs of 
a normal Wright-stained monocyte (Mo) and neutrophil (Ne) from the 
blood of mice reconstituted with control vector HSCs, and two examples 
of the Wright-stained irregular myeloid cells found in MG155 HSC-recon-
stituted animals (bar, 5     m). (C) RBC, hemoglobin (Hb), platelet, white 
blood cell, B220 B cell, and CD4 T cell levels in the blood of mice reconsti-
tuted with MG155 or control vector HSCs. (D) Microscopic photographs 
of Wright-stained peripheral blood RBCs from mice reconstituted with 
MG155 or control vector HSCs (bar, 10     m). Data represent at least nine 
independent animals in each group, and p-values (*) of   <  0.05 were con-
sidered signifi  cant after a Student  ’  s two-tailed   t   test.   JEM VOL. 205, March 17, 2008 
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    MiR-155   can directly repress genes implicated 
in hematopoietic development and disease 
  MiRNAs exert their biological functions through the degrada-
tion and/or translational repression of target mRNAs. To iden-
tify   miR-155   target genes that may be involved in the observed 
myeloproliferative phenotype, we fi  rst transduced RAW 264.7 
myeloid cells with a   miR-155    –  expressing retrovirus that in-
creased mature   miR-155   cellular levels within twofold of those 
observed after LPS stimulation (Fig. S4, available at http://www
.jem.org/cgi/content/full/jem.20072108/DC1). A mRNA mi-
croarray analysis was next performed on RNA samples collected 
from   miR-155    –  expressing and control cells to identify genes 
regulated by   miR-155   (Fig. S5). Some 1,080 transcripts were 
down-regulated   >  1.2-fold with a p-value of   <  0.08, and 89 of 
the repressed mRNAs contained conserved (human and mouse) 
  miR-155   binding sites with 7- or 8-mer seeds in their 3     UTRs 
according to published lists of computationally predicted target 
genes found on the Targetscan 4.0 website (  19, 20  ). Finally, 
genes with reported roles in myeloid hyperplasia and/or hema-
topoiesis were identifi  ed through literature searching. Using 
these criteria, our attention was drawn to 10 candidate targets: 
Bach1, Sla, Cutl1, Csf1r, Jarid2, Cebp    , PU.1, Arntl, Hif1    , and 
Picalm (  Fig. 6 A  ).   To confi  rm the microarray results, quantita-
tive PCR was performed using gene-specifi  c primers. It showed 
that the mRNAs encoding these proteins were down-regulated 
    20  –  70% in RAW 264.7 cells expressing   miR-155   versus 
empty vector control (  Fig. 6 A  ). We also observed repression of 
Cebpb, PU.1, Cutl1, and Picalm protein levels in RAW 264.7 
cells expressing   miR-155   (  Fig. 6 B  ), albeit to somewhat varying 
degrees between experiments (not depicted). 
  Next, we tested whether   miR-155   could directly repress 
the identifi  ed mRNA targets through 3     UTR interactions. 
Each full-length 3     UTR, or in two cases (Bach1 and Cebp    ) 
the region of the UTR containing the   miR-155   binding site(s), 
was cloned into a reporter vector downstream from luciferase. 
These vectors were then used to assess whether   miR-155   
could repress luciferase gene expression in 293T cells. Lucif-
erase expression was repressed between 35 and 78% depend-
ing on the 3     UTR tested (  Fig. 7  ).   There was even a rough 
correlation between the quantitative PCR results in RAW 
264.7 cells and the luciferase repression in 293T cells. To 
demonstrate a direct interaction between   miR-155   and the 
3     UTRs tested, we systematically mutated each conserved 
  miR-155   7  –   or 8-mer seed region and found that a majority of 
the miR-155  –  mediated repression was abolished (  Fig. 7  ). 
As a control,   miR-155   repressed a reporter construct contain-
ing tandem   miR-155   sites     80%. However, luciferase levels 
were relatively unaff  ected when the Traf6 or Irak1 3     UTRs 
were tested, consistent with their lack of   miR-155   binding sites 
(  Fig. 7  ). These results provide strong evidence that   miR-155   
can directly regulate several genes with relevance to hemato-
poiesis and the myeloproliferative phenotype. 
    DISCUSSION   
  As cells of the innate immune system combat infectious patho-
gens, their numbers are often depleted and must be replenished. 
decreased B220  +   B cells and CD4  +   T lymphocytes (  Fig. 4 C  ), 
and Wright staining identifi  ed several immature erythrocytes 
demonstrating polychromatophilia in   miR-155    –  expressing 
animals (  Fig. 4 D  ). 
  A subset of human AML patients overexpress   miR-155   
  Several of the pathological features observed in   miR-155    –
    expressing mice are associated with human myeloid malignan-
cies, including AML. Therefore, bone marrow samples from 
24 AML patients and 6 healthy donors were assayed for   miR-
155   and 5S expression levels by quantitative PCR. On aver-
age, the AML samples signifi  cantly overexpressed   miR-155   
compared with healthy donors, with a level approximately 
four and a half times higher (  Fig. 5 A  ).   A few AML samples 
had   miR-155   levels that were lower than the normal samples, 
whereas the overall AML sample distribution had a wide vari-
ance. In contrast, no signifi  cant diff  erence in the average ex-
pression levels of 5S RNA was observed between the groups 
(  Fig. 5 A  ).   MiR-155   levels in diff  erent subtypes of AML were 
next ascertained using the World Health Organization (WHO) 
classifi  cation system. Patients with acute myelomonocytic 
leukemia and acute monocytic leukemia, corresponding to 
FAB-AML-M4 and FAB-AML-M5, respectively, exhib-
ited signifi  cant overexpression of   miR-155   compared with 
normal samples (  Fig. 5 B  ). These observations demonstrate 
that   miR-155   expression in the bone marrow is signifi  cantly 
elevated in a subset of patients suff  ering from AML. 
    Figure 5.         Overexpression of   miR-155   in a subset of human 
AML patients  . (A) RNA was collected from the bone marrow of 6 normal 
patients and 24 patients diagnosed with AML.   MiR-155   (left) and 5S 
RNA (right) expression levels were assessed using quantitative PCR. 
(B)   MiR-155   and 5S RNA expression data were compared between 
normal subjects and AML patients of the FAB subtypes M4 and M5. 
Group differences were considered statistically signifi  cant when the 
p-value  (*)  was   < 0.05.   590    MIR-155   CAUSES A MYELOPROLIFERATIVE DISORDER | O  ’  Connell et al.
  miR-155   expression in human CD34  +   cells, a population 
containing HSCs and early progenitors of lymphoid and my-
eloid lineages (  5  ). However, defective myeloid populations 
in   miR-155    –  defi  cient mice were not observed when analyzed 
under steady-state (non-infl  ammatory) conditions (  8  ). 
  Whether   miR-155   is only suffi   cient or in fact required for 
increased myelopoiesis during infl   ammation, our fi  ndings 
demonstrate that its unregulated expression triggers a myelo-
proliferative disorder, exhibiting many preleukemic aspects. 
Because frank myeloid leukemia was not observed in any of 
This process is characterized by an increased production of 
GM populations, a response shown to involve GM-CSF  –   and 
LPS-mediated signaling events (  17, 18, 21  ). Our present fi  nd-
ings demonstrate that   miR-155   is induced by GM-CSF and LPS 
in the bone marrow compartment and is suffi   cient to increase 
the relative and absolute numbers of GM cells when expressed 
in HSCs and throughout hematopoietic development. This 
expansion appears to be at the expense of B lymphocytes and 
erythroid precursors in the bone marrow, as also observed af-
ter LPS treatment. Thus,   miR-155   may play a regulatory role 
in hematopoietic cell fates during times of infl  ammatory stress 
when factors like LPS or GM-CSF are present. Because stim-
ulation of most Toll-like receptors induces   miR-155   in mac-
rophages ( 14  ), our results with LPS can probably be generalized 
to many conditions of microbial invasion. 
  It remains unclear whether   miR-155   participates in hema-
topoiesis under steady-state conditions. A recent study detected 
    Figure 6.         Repression of specifi  c target genes involved in myeloid 
hyperplasia and/or hematopoiesis by   miR-155  .   (A) Messenger RNA 
from Raw 264.7 cells infected with MSCVpuro-155 or empty vector con-
trol was subjected to a microarray analysis, and results indicate expres-
sion changes mediated by   miR-155  . The intensities of red and green 
correlate with increased or decreased mRNA levels, respectively, and nu-
merical repression values for each mRNA are listed. RNA from the same 
cell types were converted to cDNA and used to assay expression of these 
genes by quantitative PCR (mean   ±   SD). All values have been normalized 
to L32 mRNA levels, are displayed as percent expression of control, and 
are the average of three independent experiments. (B) Western blotting 
was performed to assay Cebpb, PU.1, Cutl1, Picalm, or    Tubulin  using 
extract from Raw 264.7 cells stably expressing   miR-155   or empty vector, 
and data are representative of at least three independent experiments 
(left and middle). Expression of   miR-155   in Raw 264.7 cells infected with 
MSCVpuro-155 or empty vector control was assayed by Northern blotting 
to ensure proper expression of mature   miR-155   (right).   
    Figure 7.           MiR-155   repression of specifi  c target genes occurs 
through direct 3     UTR interactions.   (A) The 3     UTR regions from identi-
fi  ed   miR-155   target mRNAs containing   miR-155   binding site(s) with con-
served 7- or 8-mer seeds (gray boxes), nonconserved 7-mer seed (Arntl, 
white box), or conserved 6-mer seed (Cutl1, white box) were cloned 
downstream from luciferase (pmiReport vector). Mutations to these spe-
cifi  c seed regions are marked with an X. The region of the 3     UTR cloned is 
designated with a red line, and the cartoon schematics of the UTRs are 
not drawn to scale. These constructs were used for reporter assays in 
293T cells by cotransfection with a control    -galactosidase  expression 
plasmid and a   miR-155   expression vector (FUW-155) or empty vector 
control (FUW). A positive control vector contained tandem   miR-155   bind-
ing sites, whereas negative controls contained no 3     UTR or the 3     UTR 
from Irak1 or Traf6, which lack   miR-155   sites. Data using WT 3     UTRs  are 
in black, and mutant UTRs are in gray. All luciferase values have been 
normalized to     -galactosidase and are represented as percent luciferase 
expression of control (mean   ±   SD). All data are a triplicate set represent-
ing at least three independent experiments.     JEM VOL. 205, March 17, 2008 
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  In an eff  ort to explore the mechanistic basis for the myelo-
proliferative phenotype caused by HSC expression of   miR-155  , 
we identifi  ed several mRNA targets that were directly re-
pressed by   miR-155   according to 3     UTR reporter assays. 
Of note, the reduced expression or altered function of some of 
these targets has been linked to AML, as in the case of PU.1 
and Picalm (  24, 25  ), or myeloproliferative conditions, as is 
true for Cutl1 and Csf1r (  26, 27  ). Other identifi  ed targets 
have been implicated in control of various aspects of hemato-
poiesis involving many of the cell types that are perturbed in 
mice expressing   miR-155   in HSCs. These include Cebpb (  28  ), 
Bach1 (  29  ), Arntl (  30  ), Sla (  31  ), Jarid2 (  32  ), and Hif1     (  33  ). 
Thus,   miR-155   could mediate its overall biological aff  ects, 
both physiological and pathological, through the combinatorial 
repression of a broad range of targets in a variety of cell types. 
Such a multi-target regulation has recently been described for 
T cell receptor signaling (  34  ). Therefore, it is possible that 
complete rescue of this phenotype will not be achieved 
through replacing any one of the specifi  c   miR-155   target genes. 
However, the specifi  c spatial and temporal contributions of 
individual targets to the myeloproliferative phenotype and 
AML in the context of   miR-155   repression remain an area for 
future investigation. 
  There is emerging evidence that individual miRNAs are 
part of a more complex regulatory network involving other 
miRNAs and transcriptional regulators that cooperate to gov-
ern myelopoiesis. For example, Csf1r is important for monocyte 
development and has recently been reported to be regu-
lated indirectly by miRNAs 17-5p-20a-106a (  26  ). miRNAs 
17-5p-20a-106a repress the transcriptional regulator AML1 
required for Csf1r transcription. Therefore, both miRNAs 
17-5p-20a-106a and   miR-155   can infl  uence Csf1r expression 
through diff  erent mechanisms. In the case of   miR-155   targets 
PU.1 and Cebpb, they have been shown to transcriptionally 
regulate expression of myeloid-specifi  c miR-223 (  35  ). miR-223 
is subsequently involved in unleashing CEBP     function, a 
central transcription factor in myelopoiesis, through the di-
rect repression of its inhibitor, NFI-A (  36  ). Such dynamic 
systems require appropriate miRNA expression levels and ki-
netics to carefully orchestrate hematopoietic development, as 
has been recently described during T cell development in the 
thymus (  37  ). However, it is easy to see how this delicate process 
would be vulnerable to dysregulated miRNA expression 
leading to pathological outcomes. This concept is exempli-
fi  ed by the dysplastic features observed in many GM cells 
from our   miR-155    –  expressing mice. It is possible that although 
initial   miR-155   expression expands GM numbers, its timely 
down-regulation is necessary for these cells to complete their 
developmental programs. Such a model would be consistent 
with the transient expression of   miR-155   that precedes expan-
sion of morphologically normal GM populations in the bone 
marrow after LPS treatment. 
  Based upon our current study,   miR-155   appears to play a 
role in promoting GM cell expansion during infl  ammatory 
responses while initiating pathological processes under forced 
expression. Due to the enhanced expression of   miR-155   in a 
our mice analyzed within 2 mo of reconstitution with   miR-155  -
expressing HSCs, such a transition may require additional 
mutations. However, the relevance of our observed pheno-
type in mice is substantiated by the elevated expression levels 
of   miR-155   seen in human patients with AML. Interestingly, 
the two AML subgroups found to be overexpressing   miR-155   
are characterized as myelomonocytic (M4) and monocytic 
(M5), both thought to be derived from cells demonstrating 
aspects of GM cell diff  erentiation, similar to the expanded GM 
cells in our   miR-155    –  expressing mice. It is of note that   miR-155   
may also be elevated in other subtypes of AML where we did 
not have enough samples to make such a conclusion. If   miR-155   
does prove to be dysregulated in specifi  c subtypes of AML, it 
might complement the recent fi  nding that miR-181 expres-
sion positively correlates with M1 and M2 subtypes of AML, 
but not M4 or M5 (  22  ). Furthermore, as the full spectrum of 
miRNAs that become dysregulated during AML is defi  ned, 
these small RNAs may prove to have utility as diagnostic in-
dicators of AML subtypes. 
  Despite the similarities mentioned above, certain aspects 
of the   miR-155    –  induced myeloproliferative phenotype were 
not observed during the 3-d analysis period after LPS-mediated 
acute infl  ammation, such as GM dysplasia, peripheral blood 
leukopenia and polychromatophilic RBCs, and reduced mega-
karyocyte and platelet levels (not depicted). These observa-
tions may refl  ect a diff  erential eff  ect of sustained   miR-155   
expression in cell types that require strictly regulated levels of 
this miRNA. However, chronic infl  ammation (which may also 
sustain high   miR-155   expression levels) might trigger some of 
these pathological events given enough time. For instance, 
after months of polymicrobial sepsis in mice, there is reported 
extramedullary hematopoiesis in the spleen and signifi  cantly 
increased numbers of morphologically heterogeneous GM 
cells in both the spleen and bone marrow compartments (  23  ). 
The infl  ammatory response in the bone marrow involves 
profound myeloid proliferation and, through factors such 
as   miR-155  , may prove to create a microenvironment suit-
able for cancer formation and development if not resolved 
in a timely manner. 
  Unlike a previous report, which found that B cell  –  restricted 
transgenic expression of   miR-155   triggers B cell lymphoma 
in mice (  7  ), we did not observe a B cell malignancy in our 
model. This may be explained by diff  erences in the systems 
used because our model allows for   miR-155   expression be-
ginning in adult HSCs, which precedes formation of pro  –  B 
cells during hematopoietic development (  1  ). These observa-
tions suggest that   miR-155   may trigger unique phenotypes 
when expressed at diff  erent stages or in distinct cell type(s) 
during hematopoiesis. There is also evidence that developing 
B cells and GMs may occupy an overlapping bone marrow 
niche. Based upon our current fi  ndings,   miR-155   expression 
may allow for GM progenitors to dominate this compart-
ment and inhibit B cell development, which has been pro-
posed to occur during infl  ammation (  17  ). This mechanism 
might also block events required for   miR-155    –  dependent B 
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  RNA quantifi  cation.     Northern blotting and quantitative PCR were used 
to assay   miR-155   and other mRNAs as described previously (  14  ). Gene-specifi  c 
primer sequences used for quantitative PCR are shown in Table S3. For the 
microarray study, total RNA was collected from fi  ve RAW 264.7 stably in-
fected clones expressing   miR-155   or empty vector using the RNeasy Mini 
kit per the manufacturer  ’  s instructions (QIAGEN). The Aff  ymetrix Mouse 
Genome 430 2.0 microarray analysis was then performed using pooled RNA 
from each group by the Millard and Muriel Jacobs Genetics and Genomics 
Laboratory at Caltech according to detailed protocols (http://aff  ymetrix.com/
products/arrays/specifi  c/mouse430_2.aff  x). Data were analyzed using Rosetta 
Resolver Software. Microarray data were deposited in the GEO database 
under accession number   GSE10467  . 
  Western blotting.     Western blotting was performed using standard protocols 
and the following antibody clones from Santa Cruz Biotechnology, Inc.: Cebpb 
(C-19), PU.1 (T-21), Cutl1 (M-222), Picalm (C-18), and     Tubulin (AA12). 
Protein expression diff  erences were determined using Scion Image software. 
  Flow cytometry and cell separation.     Fluorophor-conjugated monoclonal 
antibodies specifi  c for either Mac1, Gr1, Ter-119, B220, and CD4 (all from 
eBioscience) were used in various combinations to stain RBC-depleted 
splenocytes, bone marrow, or peripheral blood mononuclear cells that were 
fi  xed after washing using paraformaldehyde (1% fi  nal). Stained cells were assayed 
using a BD FACSCalibur fl  ow cytometer and further analyzed with FloJo 
software. Cell separation was performed using biotinylated monoclonal anti-
bodies against Mac-1, Ter-119, and B220 (eBioscience), streptavidin-con-
jugated magnetic beads (Miltenyi Biotec), and MACS LS Separation Columns 
(Miltenyi Biotec). 
  Luciferase reporter assays.     8   ×   10  4   293T cells were plated in DMEM 
media containing 5% FBS for 18 h, followed by transfection of relevant plas-
mids using lipofectamine (Invitrogen) per the manufacturer  ’  s instructions. 
Luciferase assays were performed 48 h later using a dual luciferase kit (Promega). 
A     -gal expression plasmid was cotransfected and     -gal levels were assayed 
and used to normalize the luciferase values. 
  Human AML sample collection and analysis.     Bone marrow biopsy 
samples collected from patients with AML were fl  ash-frozen and stored at 
    80  °  C after the completion of diagnostic work in a tissue bank at University 
of California, Los Angeles. For this study, 24 samples were rapidly thawed 
and subjected to TRIzol purifi  cation of RNA. In addition, six RNA samples 
were isolated from healthy donors. AML cases were categorized according to 
the WHO   “  Classifi  cation of Tumors  ”   using anonymous clinical reports. All 
work performed on these tissues was approved by the Institutional Review 
Board at UCLA. 
  Morphological assessment of hematolymphoid tissues.     For histological 
sectioning, organs were placed into 10% neutral-buff  ered formalin immediately 
after necropsy, fi  xed for 12  –  18 h, washed, and transferred to 70% ethanol 
before standard paraffi   n embedding, sectioning, and staining with hematoxy-
lin and eosin. Bones were also decalcifi  ed. For cytological assessment, touch 
preparations of the cut surface of the spleen were performed. Peripheral 
blood smears were obtained from tail vein bleeds or from the heart at nec-
ropsy. Bone marrow smears were prepared from extracted bone marrow of 
reconstituted mice. All cytological preparations were air-dried and stained 
with Wright  ’  s stain. Both histological and cytological preparations were 
  examined on an Olympus BX-51 microscope and photographed using a 
Spot Digital Camera and software. Complete blood cell counts were per-
formed at UCLA  ’  s Department of Laboratory Animal Medicine. 
  Statistical tests.     All statistical analyses were performed using Microsoft Excel 
statistical software module. For patient samples, an F-test determined that the 
distributions of   miR-155   expression in normal samples versus AML samples 
were heteroscedastic (P = 4.5   ×   10      6   for F-test). Similarly, the distributions 
of   miR-155   expression in normal versus AML-M4 was determined to be 
subset of AML patients, and its ability to repress several genes 
relevant to myeloid malignancies, therapeutic targeting of 
  miR-155   with such agents as antagomirs may provide a benefi  -
cial option (  38  ). Because   miR-155   knockout mice display few 
detrimental phenotypes in the absence of infection (  8  ), de-
creasing   miR-155   function in human patients suff  ering from 
myeloid, lymphoid, or other malignancies correlated with 
enhanced   miR-155   expression may provide more benefi  ts 
than harm. 
  MATERIALS AND METHODS 
  Cell culture and reagents.     RAW 264.7 and 293T cells were both cul-
tured in complete DMEM containing 10% FBS, 100 U/ml penicillin, and 
100 U/ml streptomycin with 5% C0  2  . Mouse bone marrow  –  derived macro-
phages were made using M-CSF  –  containing media. LPS from   Escherichia coli   
strain 055:B5 was purchased from Sigma-Aldrich, and recombinant mouse 
GM-CSF was purchased from eBioscience. 
  DNA constructs.     A   miR-155   expression cassette containing the human 
  miR-155   hairpin sequence and fl  anking regions was cloned from a B cell 
cDNA library into pcDNA3 as described previously (  12  ). This cassette was 
subcloned into pMSCVpuro, FUW, or pMG. pMG155 is a modifi  ed MSCV 
vector whereby GFP was placed downstream from the 5     LTR, and the 
  miR-155   expression cassette was cloned downstream from the GFP stop codon 
(detailed cloning strategy available upon request). For reporter assays, the 
3    UTRs of the respective mRNAs were cloned into pmiReport (Ambion) 
after amplifi  cation from a mouse macrophage cDNA library. Primer sequences 
are described in Table S1, which is available at http://www.jem.org/cgi/
content/full/jem.20072108/DC1. The Bach1 3     UTR region was amplifi  ed 
from a human B cell library. Site-directed mutagenesis was used to change spe-
cifi  c nucleotides found within the   miR-155   seed regions (Table S2). The 2-mer 
control insert consists of a tandem repeat of the complimentary sequence to 
the mature mouse   miR-155   sequence. Cloning of the TRAF6 and IRAK1 3     
UTR into pmiReport was described previously (  15  ). 
  Mice.     WT C57BL6 mice were purchased from The Jackson Laboratory, 
and Rag1      /      mice were bred in-house. All experiments involved female 
mice and were performed according to IACUC-approved protocols. 
  Retroviral infections, stable cell lines, and bone marrow reconstitution.   
  To generate VsVg-pseudotyped retroviruses containing the   miR-155   ex-
pression cassette, 2   ×   10  6   293T cells were transfected with pMSCVpuro  –   
miR-155  , pGag-Pol, and pVsVg using a standard calcium phosphate protocol. 
After 48 h, viral supernatant was harvested and used to infect 5   ×   10  5   RAW 
264.7 cells for 8 h in the presence of polybrene at 10     g/ml. After 48 h, sta-
bly transduced cells were selected using puromycin at 7     g/ml for 7  –  10 d, 
and   miR-155   expression was assessed at the same time as experiments were 
performed by Northern blotting or quantitative PCR for all batches made. 
  To obtain HSC-enriched bone marrow cells, mice were injected i.p. 
with 5     g 5-fl  uorouracil for 5 d before bone marrow harvest (  39  ). Cells were 
collected from the bone marrow, and RBCs were removed using an RBC 
lysis solution (Invitrogen). Cells were cultured for 24 h in 20 ng/ml IL-3, 
50 ng/ml IL-6, and 50 ng/ml SCF (all from eBioscience) containing complete 
RPMI (10% FBS, 100 U/ml penicillin, 100 U/ml streptomycin, and 50     M 
    -marcaptoethanol) before initial retroviral infection. To generate retrovi-
ruses for infecting HSC-enriched bone marrow cells, 293T cells were trans-
fected with pMG155 and pCL-Eco. After 48 h, 8     g/ml polybrene was 
added to culture supernatant  –  containing retroviruses, and this was used to 
spin-infect 10  6   HSC-enriched cells per donor for 1.5 h at 2,500 RPM and 
30  °  C. This procedure was repeated three times once daily, followed by in-
jection of 10  6   retrovirally infected HSC-enriched cells per lethally irradiated 
(1,100 rads from Cesium 137 source at 50 rads/minute) recipient. Recipients 
were maintained on Septra throughout the reconstitution period. JEM VOL. 205, March 17, 2008 
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heteroscedastic (P = 1.8   ×   10      5   for F-test). After this, a two-tailed   t   test was 
performed assuming heteroscedastic distributions for both comparisons. For all 
other data, a Student  ’  s two-tailed   t   test was used. 
  Online supplemental material.     Fig. S1 demonstrates that both immature 
and mature cell-enriched bone marrow populations up-regulate   miR-155   in 
response to LPS. Fig. S2 provides FACS data showing the percentage of 
Mac1  +  , Gr1  +  , B220  +  , Ter-119  +  , or CD4  +   cells in the bone marrow after 24 
h of LPS versus PBS treatment. Fig. S3 presents the coexpression of   miR-155   
and GFP in several diff  erent immune organs from reconstituted mice. Fig. S4 
compares   miR-155   expression in Raw 264.7 cells and primary macrophages 
mediated by retroviral overexpression versus LPS stimulation. Fig. S5 out-
lines the scheme used to identify   miR-155   targets with relevance to hemato-
poiesis. Table S1 provides the primer sequences used for cloning diff  erent 3     
UTRs into pmiReport. Table S2 provides sequence information regarding 
mutations introduced into the 3     UTRs used for reporter assays. Table S3 
provides the primer sequences used to assay   miR-155   target mRNAs by 
quantitative PCR. The online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20072108/DC1. 
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